We have ordered more raw materials as well as working with some other groups to do some of the contract manufacturing, to do some of our final kitting of our product. RAYCHAUDHURI: Well, we have been hiring a lot. ![]() And then we want to scale up very quickly to 5 to 10 million in the next month or so.įLORIDO: And what have you done to try to make sure that you get there? Our production targets are 2 million tests per week. ![]() And so we have been ramping up to get all of our materials in place, our printed materials in place. RAYCHAUDHURI: Well, we only recently received emergency use authorization for our tests from the FDA. How many tests were you producing before demand started to surge, and what are your targets now? Estella Raychaudhuri, thanks for joining us today.ĮSTELLA RAYCHAUDHURI: Thank you for having me.įLORIDO: Your company has spent the last few weeks trying to ramp up production of these rapid tests. Estella Raychaudhuri is president of InBios International, based in Seattle. To find out what that looks like and how it's going, we've called the leader of one test manufacturer. That and the broader demand from consumers has test manufacturers rushing to ramp up production. And last month, the Biden administration announced its plan to distribute 500 million rapid tests to Americans who request them. Given the fast spread of the omicron variant, the tests have become an important tool for people who want to quickly find out if they've been infected. ![]() And if you can find them, major retailers, like CVS, Walmart and Amazon, have imposed limits on how many you can buy. Amid the current surge of infections, demand for the tests has soared. The hottest commodity of the new year may very well be COVID-19 at-home rapid tests.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |